- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02587650
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
A Phase II Trial of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma
Study Overview
Status
Conditions
- ALK Fusion Protein Expression
- Stage III Cutaneous Melanoma
- Stage IIIA Cutaneous Melanoma
- Stage IIIB Cutaneous Melanoma
- Stage IIIC Cutaneous Melanoma
- Stage IV Cutaneous Melanoma
- ROS1 Fusion Positive
- BRAF wt Allele
- Invasive Skin Melanoma
- MET Fusion Gene Positive
- NRAS wt Allele
- NTRK1 Fusion Positive
- NTRK2 Fusion Positive
- NTRK3 Fusion Positive
- RET Fusion Positive
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To estimate the clinical activity of tyrosine kinase inhibitors matched to the tumor-specific fusion kinase in patients with metastatic melanoma.
SECONDARY OBJECTIVES:
I. To estimate tumor stability in melanoma patients treated with kinase inhibitors matched to the tumor-specific fusion kinase.
II. To estimate survival in melanoma patients treated with kinase inhibitors matched to the tumor-specific fusion kinase.
III. To examine the safety and tolerability of kinase inhibitors in patients with melanoma with a fusion kinase.
TERTIARY OBJECTIVES:
I. To explore molecular mechanisms of resistance for patients who progress on therapy.
OUTLINE: Patients are assigned to 1 of 4 arms.
ARM A: Patients with MET fusion receive capmatinib orally (PO) twice daily (BID) on day 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
ARM B: Patients with ALK fusion receive ceritinib PO once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
ARM C: Patients with RET or BRAF fusion receive regorafenib PO QD on day 1-21. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
ARM D: Patients with NTRK1, NTRK2, NTRK3, or ROS1 fusion receive entrectinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
After completion of study treatment, patients are followed up within 30 days and then periodically.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94115
- University of California, San Francisco
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
CAPMATINIB INCLUSION CRITERIA:
- Ability to understand a written informed consent document, and the willingness to sign it
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Life expectancy >= 12 weeks
- Histologically or cytologically confirmed invasive melanoma
- Unresectable stage III or stage IV melanoma by clinical or radiographic criteria
- Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
- Documentation of absence of activating and targetable BRAF or NRAS point mutations
- Presence of an oncogenic kinase fusion involving MET, confirmed by assay by a Clinical Laboratory Improvement Act (CLIA)-approved laboratory
- Prior treatment with at least one Food and Drug Administration (FDA)-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician
- Resolution of all acute toxic effects (excluding alopecia) of prior radiotherapy, chemotherapy or surgical procedures to Common Terminology Criteria for Adverse Events (CTCAE) v4.03 grade =< 1
- Absolute neutrophil count >= 1,500/mm^3
- Platelets >= 75,000/ microliters (mcL)
- Hemoglobin >= 9 g/dL (transfusions are allowed)
- Total bilirubin =< 1.5 x upper limit of normal (ULN); patients with Gilbert?s syndrome may be included if total bilirubin =< 3 x ULN or direct bilirubin =< 1.5 x ULN
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x ULN if no liver metastases are present? =< 5 x ULN if liver metastases are present
- Alkaline phosphatase (ALP) =< 5 x ULN
- Serum amylase =< grade 2 and asymptomatic; patients with grade 1 or 2 serum amylase at the beginning of the study must be confirmed to have no signs and/or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.)
- Serum lipase =< ULN
- Creatinine OR creatinine clearance within normal limits > 40 mL/min (calculated by Cockgraft-Gault) for patients with creatinine levels above ULN
- Serum potassium, calcium (corrected for serum albumin), magnesium, phosphorus within normal limits with or without supplementation
CERITINIB INCLUSION CRITERIA:
- Ability to understand a written informed consent document, and the willingness to sign it
- ECOG performance status 0-1
- Life expectancy >= 12 weeks
- Histologically or cytologically confirmed invasive melanoma
- Unresectable stage III or stage IV melanoma by clinical or radiographic criteria
- Measurable disease by RECIST v1.1
- Documentation of absence of activating and targetable BRAF or NRAS point mutations
- Presence of an oncogenic kinase fusion involving ALK, confirmed by assay by a CLIA-approved laboratory
- Prior treatment with at least one FDA-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician
- Resolution of all acute toxic effects (excluding alopecia) of prior radiotherapy, chemotherapy or surgical procedures to CTCAE v4.03 grade =< 1
- Absolute neutrophil count >= 1.5 x 10^9/L
- Platelets >= 75 x 10^9/L
- Hemoglobin >= 8 g/dL (transfusions are allowed)
- Total bilirubin =< 1.5 x upper limit of normal (ULN); patients with Gilbert?s syndrome may be included if total bilirubin =< 3 x ULN and direct bilirubin =< 1.5 x ULN
- AST (SGOT) and ALT (SGPT) =< 3 x ULN if no liver metastases are present? =< 5 x ULN if liver metastases are present
- Alkaline phosphatase (ALP) =< 5 x ULN
- Serum amylase =< 2 x ULN
- Serum lipase =< ULN
- Fasting plasma glucose =< 175 mg/dL (=< 9.8 mmol/L)
- Creatinine OR creatinine clearance < 1.5 mg/dL >= 30 mL/min (calculated by Cockgraft-Gault) for patients with creatinine levels above ULN
- Serum potassium, calcium (corrected for serum albumin), magnesium, phosphorus within normal limits with or without supplementation
REGORAFENIB INCLUSION CRITERIA:
- Ability to understand a written informed consent document, and the willingness to sign it
- ECOG performance status 0-1
- Life expectancy >= 12 weeks
- Histologically or cytologically confirmed invasive melanoma
- Unresectable stage III or stage IV melanoma by clinical or radiographic criteria
- Measurable disease by RECIST v1.1
- Documentation of absence of activating and targetable BRAF or NRAS point mutations
- Presence of an oncogenic kinase fusion involving BRAF or RET, confirmed by assay by a CLIA-approved laboratory
- Prior treatment with at least one FDA-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician
- Resolution of all acute toxic effects (excluding alopecia) of prior radiotherapy, chemotherapy or surgical procedures to CTCAE v4.03 grade =< 1
- Absolute neutrophil count >= 1,500/mm^3
- Platelets >= 100,000/mm^3
- Hemoglobin >= 9 g/dL
- Total bilirubin =< 1.5 x upper limit of normal (ULN); patients with Gilbert?s syndrome may be included if total bilirubin =< 3 x ULN or direct bilirubin =< 1.5 x ULN
- AST (SGOT) and ALT (SGPT) =< 2.5 x ULN if no liver metastases are present? =< 5 x ULN if liver metastases are present
- Alkaline phosphatase (ALP) =< 2.5 x ULN if no liver metastases are present; =< 5 x ULN if bone or liver metastases are present
- Creatinine OR creatinine clearance =< 1.5 x ULN; > 40 mL/min (calculated by Cockgraft-Gault) for patients with creatinine levels above ULN
- Serum potassium, calcium (corrected for serum albumin), magnesium, phosphorus within normal limits with or without supplementation
- International normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 x ULN (patients who are prophylactically treated with an agent such as warfarin or heparin will be allowed to participate, provided that no prior evidence of underlying abnormality in coagulation parameters exists; close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is predose as defined by the local standard of care)
ENTRECTINIB INCLUSION CRITERIA:
- Ability to understand a written informed consent document, and the willingness to sign it
- ECOG performance status 0-2
- Histologically or cytologically confirmed invasive melanoma
- Unresectable stage III or stage IV melanoma by clinical or radiographic criteria
- Measurable disease by RECIST v1.1
- Patients with central nervous system (CNS) involvement, including leptomeningeal carcinomatosis, which is either asymptomatic or previously-treated and controlled, are allowed; the use of seizure prophylaxis is allowed as long as patients are taking non enzyme-inducing anti-epileptic drugs (non-EIAEDs); if patients were previously on EIAEDs and these have been discontinued, they must have been discontinued for at least 2 weeks prior to the start of entrectinib treatment; if patients require an anti-epileptic medication, a CYP3A4 non-EIAED can be used such as levetiracetam, valproic acid, gabapentin, topiramate, or lacosamide; moderate inducers of CYP450, such as dexamethasone or other glucocorticoids, may be used at the discretion of the investigator; patients requiring steroids must be at a stable or decreasing doses for at least 2 weeks prior to the start of entrectinib treatment
- Documentation of absence of activating and targetable BRAF or NRAS point mutations
- Presence of an oncogenic kinase fusion involving ROS1 or NTRK1/2/3, confirmed by assay by a CLIA-approved laboratory
- Prior treatment with at least one FDA-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician
- Resolution of all acute toxic effects (excluding alopecia) of prior radiotherapy, chemotherapy or surgical procedures to CTCAE v4.03 grade =< 1
- Absolute neutrophil count >= 1,000/mm^3
- Platelets >= 75,000/mcL
- Hemoglobin >= 8 g/dL (transfusions are allowed)
- Total bilirubin =< 1.5 x upper limit of normal (ULN); patients with Gilbert?s syndrome may be included if total bilirubin =< 3 x ULN or direct bilirubin =< 1.5 x ULN
- AST (SGOT) and ALT (SGPT) =< 3.0 x ULN if no liver metastases are present? =< 5 x ULN if liver metastases are present
- Creatinine OR creatinine clearance within normal limits; > 40 mL/min (calculated by Cockgraft-Gault) for patients with creatinine levels above ULN
Exclusion Criteria:
- CAPMATINIB EXCLUSION CRITERIA: Uveal melanoma
- CAPMATINIB EXCLUSION CRITERIA: Current participation in another therapeutic clinical trial
- CAPMATINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
- CAPMATINIB EXCLUSION CRITERIA: Previously identified allergy or hypersensitivity to components of capmatinib formulation (crospovidone, mannitol, microcrystalline cellulose, povidone, sodium lauryl sulfate, magnesium stearate, colloidal silicon dioxide, and various coating premixes)
- CAPMATINIB EXCLUSION CRITERIA: Diagnosis of concurrent malignancy or previous malignancy within 3 years before study drug administration (exceptions are superficial skin cancers, or any in situ cancers deemed surgically resected, cured and not requiring systemic therapy, and indolent malignancies that currently do not require treatment)
CAPMATINIB EXCLUSION CRITERIA: Prior treatment with the following antineoplastic therapies within the following time frame:
- Any prior treatment with capmatinib, crizotinib, or any other cMET or hepatocyte growth factor (HGF) inhibitor
- Thoracic radiotherapy to lung fields =< 4 weeks prior to starting capmatinib; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs), radiotherapy =< 2 weeks prior to starting capmatinib; palliative radiotherapy for bone lesions =< 2 weeks prior to starting capmatinib is allowed
- Receipt of any anticancer or investigational agent within 4 weeks or =< 5 half-lives of the agent (whichever is longer) prior to the first dose of capmatinib; if previous treatment is a monoclonal antibody, then the treatment must be discontinued at least 4 weeks before the first dose of capmatinib
- CAPMATINIB EXCLUSION CRITERIA: Major surgery (e.g., intrathoracic, intraabdominal or intrapelvic) within 4 weeks prior (2 weeks for resection of brain metastases) to starting capmatinib; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the study >= 1 week after the procedure
CAPMATINIB EXCLUSION CRITERIA: Patients receiving treatment with medications that meet one of the following criteria and that cannot be discontinued at least 1 week prior to the start of capmatinib treatment and for the duration of the study:
- Strong and moderate inhibitors of CYP3A4
- Strong inducers of CYP3A4
- Proton pump inhibitors (PPI)
- CAPMATINIB EXCLUSION CRITERIA: Patients on unstable or increasing doses of corticosteroids; if patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms other than CNS related, dose must have been stabilized or decreasing for at least 5 days before first dose of capmatinib
- CAPMATINIB EXCLUSION CRITERIA: Presence or history of carcinomatous meningitis
CAPMATINIB EXCLUSION CRITERIA: Known symptomatic brain metastases requiring increasing doses of steroid to manage CNS symptoms within 2 weeks prior to study entry
- Patients with asymptomatic brain metastases may be enrolled at the discretion of the sponsor as long as the patient is stable and has not required increasing dose of steroids to manage CNS symptoms for at least 2 weeks prior to study enrollment
- Patients requiring seizure prophylaxis must be taking non-enzyme-inducing anti-epileptic drugs (non-EIAED); if patients were previously on EIAEDs and these have been discontinued, they must be discontinued for at least 1 weeks prior to capmatinib administration; if patients re
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A (capmatinib)
Patients with MET fusion receive capmatinib PO BID on day 1-28.
Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
|
Correlative studies
Given PO
Other Names:
|
Experimental: Arm B (ceritinib)
Patients with ALK fusion receive ceritinib PO QD on days 1-28.
Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
|
Correlative studies
Given PO
Other Names:
|
Experimental: Arm C (regorafenib)
Patients with RET or BRAF fusion receive regorafenib PO QD on day 1-21.
Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
|
Correlative studies
Given PO
Other Names:
|
Experimental: Arm D (entrectinib)
Patients with NTRK1, NTRK2, NTRK3, OR ROS1 fusion receive entrectinib PO QD on days 1-28.
Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
|
Correlative studies
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Confirmed Overall Response Rate (ORR)
Time Frame: 24 weeks
|
Defined as a complete or partial response as per Response Evaluation Criteria in Solid Tumors version 1.1 criteria with confirmatory measurements a minimum of 4 weeks after the response-defining determination.
Analysis of study results will include ORR estimations of ALK, NTRK, ROS1, RET, MET, and BRAF rearrangement-positive patients.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Benefit Rate (CBR)
Time Frame: Up to 2 years
|
Clinical benefit rate is defined as the proportion of patients achieving a complete response (CR) or partial response (PR) or stable disease (SD) for > 24 weeks using the same RECIST 1.1 decision matrix used to calculate ORR.
The CBR will be estimated for each arm along with a 95% confidence interval
|
Up to 2 years
|
Overall Survival
Time Frame: From treatment start to death, assessed up to 2 years
|
Overall defined as the time from treatment start to the progression or death and overall survival defined as the time from treatment start to death will be estimated using Kaplan-Meier methodology.
|
From treatment start to death, assessed up to 2 years
|
Progression Free Survival
Time Frame: up to 2 years
|
Progression free survival (PFS) defined as the time from treatment start to the progression or death and overall survival defined as the time from treatment start to death will be estimated using Kaplan-Meier methodology
|
up to 2 years
|
Evaluation of the Adverse Effect Profile of Each Kinase Inhibitor
Time Frame: Up to 2 years
|
Frequencies of toxicities will be tabulated according to CTCAE v4.03 to assess drug safety and tolerability
|
Up to 2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Adil Daud, University of California, San Francisco
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Skin Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Entrectinib
- Ceritinib
Other Study ID Numbers
- 14859
- NCI-2017-01421 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ALK Fusion Protein Expression
-
Centre Leon BerardRecruitingCancer | Cancer Metastatic | ALK Fusion Protein Expression | FGFR2 Gene Translocation | FGFR3 Gene Translocation | NTRK Family Gene Mutation | Gene Fusion | ROS1 Gene Translocation | NTRK Gene Fusion Overexpression | ATIC-ALK Fusion Protein Expression | BCR-FGFR1 Fusion Protein Expression | COL1A1-PDGFB Fusion... and other conditionsFrance, Denmark, Netherlands, Austria, Germany, Italy, United Kingdom, Czechia, Poland, Slovenia, Spain
-
Sameek RoychowdhuryNational Cancer Institute (NCI)WithdrawnLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | ALK Gene Mutation | Metastatic Malignant Neoplasm in the Brain | Advanced Malignant Neoplasm | ALK Fusion Protein Expression | Metastatic Malignant Neoplasm in the Central Nervous System | ROS1 Gene Mutation | ALK Gene... and other conditionsUnited States
-
National Taiwan University HospitalNational Health Research Institutes, TaiwanRecruiting
-
Sidney Kimmel Comprehensive Cancer Center at Johns...RecruitingNSCLC Stage IV | ALK Fusion Protein ExpressionUnited States
-
Sichuan UniversityBetta Pharmaceuticals Co., Ltd.Not yet recruitingNon-Small Cell Lung Cancer | ALK Fusion Protein Expression | Adjuvant Therapy
-
Jiangsu Simcere Pharmaceutical Co., Ltd.RecruitingAdvanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene FusionChina
-
Changhai HospitalUnknownAcute Myeloid Leukemia | AML1-ETO Fusion Protein ExpressionChina
-
William ShomaliIncyte CorporationRecruitingEosinophilia | Hypereosinophilic Syndrome | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Splenomegaly | Hepatomegaly | Chronic Eosinophilic Leukemia, Not Otherwise Specified | JAK2 Gene Mutation | BCR-JAK2 Fusion Protein Expression | Blasts 20 Percent or Less of Peripheral Blood White... and other conditionsUnited States
-
Hoffmann-La RocheRecruitingALK Fusion-positive Solid or CNS TumorsUnited States, Korea, Republic of, China, Spain, Canada, United Kingdom, Australia, Denmark, France, Italy, Germany
-
Zhongda HospitalRecruitingBCR-ABL1 Fusion Protein Expression | Acute Lymphocytic Leukemia, Adult B-CellChina
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States